NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
This grant funds early phase clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders.
About this program
The NHLBI Early Phase Clinical Trials grant supports innovative research aimed at developing new therapeutics and diagnostics for heart, lung, blood, and sleep disorders. This funding opportunity is designed for researchers and institutions that are focused on advancing the understanding and treatment of these critical health issues. The grant encourages the exploration of novel approaches and methodologies in clinical trial design to improve patient outcomes and enhance the quality of care in HLBS disorders. Eligible applicants include academic institutions, nonprofit organizations, and other research entities that have the capacity to conduct early phase clinical trials. The grant aims to foster collaboration among researchers, healthcare providers, and industry partners to accelerate the translation of scientific discoveries into clinical applications. By providing financial support for these trials, the NHLBI seeks to promote advancements in medical science that can lead to significant improvements in public health.
Eligibility
Academic institutions, nonprofit organizations, and research entities with the capacity to conduct early phase clinical trials.